• Molecular NameLapatinib
  • SynonymFMM; GW 572016; GW572016; lapatinib; Lapatinib ditosylate; Lapatinib tosilate hydrate
  • Weight581.068
  • Drugbank_IDDB01259
  • ACS_NO231277-92-2
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)5.45
  • pkaN/A
  • LogD (pH=7, predicted)5.43
  • Solubility (experiment)0.007 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-7.93
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors2
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds11
  • TPSA114.73
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn orally active chemotherapeutic drug treatment for solid tumours such as breast cancer.
  • Absorption_valueN/A
  • Absorption (description)Oral absorption is incomplete and variable.
  • Caco_2N/A
  • Bioavailability50.0
  • Protein binding99.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic, mostly CYP3A-mediated (minor 2C19 and 2C8 involvement)
  • Half life24 h
  • ExcretionMostly fecal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAdverse reactions occurring in ?10% of Patients include gastrointestinal disorders, skin and subcutaneous tissue disorders, mucosal inflammation, pain, dyspnea, insomnia
  • LD50 (rat)N/A
  • LD50 (mouse)N/A